Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
DBGen Ocular Genomics | RCV001591784 | SCV001815877 | pathogenic | Retinitis pigmentosa | 2021-06-16 | criteria provided, single submitter | clinical testing | |
DBGen Ocular Genomics | RCV003389497 | SCV004101718 | pathogenic | Autosomal recessive optic atrophy | 2021-01-01 | criteria provided, single submitter | clinical testing | Class 5 ACMG Guidelines, 2015 (PMID:25741868) |
Labcorp Genetics |
RCV003771780 | SCV004605079 | likely pathogenic | Cone-rod dystrophy 6; Leber congenital amaurosis 1 | 2023-09-30 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 1213843). This variant has not been reported in the literature in individuals affected with GUCY2D-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 6 of the GUCY2D gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GUCY2D are known to be pathogenic (PMID: 10951519, 11328726). |